Skip to main content

Table 3 SIRs and HRs for myeloma after a specified AI disease by diagnostic period of cancer

From: Effect of autoimmune diseases on incidence and survival in subsequent multiple myeloma

Autoimmune disease(case numbers in the two periods)

1964-1990

1991-2008

Pyrs

O

SIR

95%CI

Deaths

HR

95%CI

Pyrs

O

SIR

95%CI

Deaths

HR

95%CI

Ankylosing spondylitis (4692/1954)

39322

3

1.73

0.33-5.12

1

3.60

0.50-25.72

73502

13

2.09

1.11-3.59

2

0.40

0.10-1.59

Behcet disease (3635/239)

28513

3

2.14

0.40-6.35

3

1.38

0.45-4.29

34669

3

1.12

0.21-3.33

0

  

Chronic rheumatic heart disease (17015/4012)

85701

13

1.16

0.62-1.99

6

1.55

0.70-3.46

80541

10

0.73

0.35-1.35

2

0.43

0.11-1.73

Crohn disease (12733/12944)

110614

3

1.01

0.19-3.00

1

1.19

0.17 -8.43

281650

12

0.78

0.40-1.37

6

1.22

0.55-2.71

Graves/hyperthyroidism (26633/15387)

203693

22

1.32

0.82-2.00

8

0.61

0.31-1.23

337411

30

0.89

0.60-1.27

15

1.17

0.71-1.95

Hashimoto/hypothyroidism (8375/4785)

43501

8

1.88

0.80-3.72

3

1.16

0.37-3.59

77204

7

0.79

0.31-1.64

0

  

Immune thrombocytopenic purpura (965/3359)

8640

1

4.44

0.00-25.4

1

0.53

0.07-3.73

355800

3

1.81

0.34-5.37

1

0.61

0.09-4.35

Multiple sclerosis (8782/5834)

67706

4

1.03

0.27-2.67

2

4.02

1.01-16.01

117308

9

0.97

0.44-1.86

5

1.14

0.47-2.73

Myasthenia gravis (1551/1493)

10430

2

2.91

0.27-10.7

0

  

22218

2

0.88

0.08-3.23

2

1.92

0.48-7.67

Pernicious anemia (9687/1903)

32746

5

0.83

0.26-1.96

3

0.72

0.23-2.22

34350

8

1.17

0.50-2.32

7

1.37

0.66-2.88

Polymyalgia rheumatica (13278/14256)

72444

10

1.59

0.76-2.94

5

1.35

-0.563.24

180602

33

1.12

0.77-1.57

18

0.92

0.581-1.46

Polymyositis/dermatomyositis (1295/1170)

8310

1

1.57

0.00-9.00

0

  

15731

3

1.89

0.36-5.59

3

6.44

2.08-20.0

Psoriasis (14068/5709)

112458

11

1.51

0.75-2.71

5

0.78

0.32-1.88

163513

12

0.74

0.38-1.30

2

0.31

0.08-1.24

Rheumatic fever (3888/418)

34274

4

2.05

0.53-5.30

2

5.06

1.26-20.28

43114

4

0.99

0.26-2.57

3

4.43

1.43-13.7

Rheumatoid arthritis (49139/23170)

304697

35

1.02

0.71-1.41

16

0.81

0.49-1.32

427257

46

0.80

0.58-06

25

1.19

0.80-1.77

Sarcoidosis (7856/3715)

69124

9

2.17

0.98-4.14

6

1.31

0.59-2.93

108641

10

0.95

0.45-1.76

3

0.75

0.24-2.32

Sjögren syndrome (716/1241)

3386

1

3.10

0.00-17.7

1

0.87

0.12-6.15

13314

3

1.89

0.36-5.60

0

  

Systemic lupus erythematosus (4717/2907)

31854

4

1.93

0.50-4.99

4

15.48

5.79-41.42

54773

7

1.60

0.64-3.32

1

0.25

0.04-1.80

Systemic sclerosis (5795/1374)

36494

10

3.60

1.71-6.64

7

0.91

0.43-1.93

53503

9

2.02

0.92-3.85

5

1.35

0.56-3.25

Ulcerative colitis (17071/16422)

136018

5

0.95

0.30-2.23

1

0.27

0.04-1.95

350686

33

1.45

1.00-2.04

19

1.46

0.93-2.29

Wegener granulomatosis (14233/1600)

61898

14

1.20

0.65-2.02

3

0.32

0.10-1.00

53848

12

1.14

0.59-2.00

10

1.22

0.66-2.28

All (253449/149013)1696388

1696388

171

1.31

1.12-1.52

78

0.88

0.70-1.10

3081277

286

1.04

0.92-1.16

137

0.99

0.99-1.17

  1. Bold type indicates that the 95% CI does not include 1.00.
  2. Abbreviations: Pyrs, person-years; O, observed; SIR, standardized incidence ratio; CI, confidence interval; HR, hazard ratio.